Fidson H1 2025 review
Here's my first of 3 episodes on pharma firms H1 2025 earnings on the NGX.
I walk through Fidson H1 2025 earnings as well as my near and mid term price targets.
As always, please note that this is not investment or trading advice.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.